|Bid||90.17 x 1300|
|Ask||93.00 x 900|
|Day's Range||86.58 - 95.20|
|52 Week Range||3.84 - 100.65|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.00|
With all of the recent news around a new treatment for Alzheimer's disease (AD), the huge gains by smaller biotechs developing treatments can get lost. Now that the Food and Drug Administration has approved Biogen's (NASDAQ: BIIB) Aduhelm despite its mixed results, it theoretically made it much easier for new treatments to get the green light. Unlike most AD drugs, Annovis Bio's ANVS401 isn't designed to get rid of amyloid in the brain.
When the Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) aducanumab -- now marketed as Aduhelm -- for treating Alzheimer's Disease, it marked the end of a long drought. No matter how that turns out, the low bar for approval set by the FDA is likely to open the floodgates for Alzheimer's treatments. It has investors in Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSEMKT: ANVS) excited about their candidates, which are currently in clinical trials.
Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its participation in 2021 BIO Digital, the premier biotech event, taking place online June 10-11 & 14-18, 2021.A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to register